Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tysabri Cost Data Shows Up To $23,274 Benefit Over Other MS Therapies

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec/Elan report data showing a treatment cost benefit with Tysabri based on multiple sclerosis relapses avoided.

You may also be interested in...

Tysabri Re-Launches In U.S. Through Single Distributor

Biogen Idec/Elan's multiple sclerosis therapy Tysabri is available in the U.S. through a single distributor: AmerisourceBergen Specialty Group division ICS

ICER Hands CMS A Drug Price Negotiation Cheat Sheet

The drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.

Blueprint’s Evolution On Its Path To Financial Sustainability

Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts